Slide 1: Fourth Quarter 2007 Webcast
Exhibit 99.1 Fourth Quarter 2007 Webcast February 7, 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially. This presentation is being made on February 7, 2008, and Alcon does not undert
Slide 3: Business Overview
Business Overview Cary Rayment Chairman, President & CEO 3
Slide 4: Sales Highlights
Sales Highlights 4th Qtr Q4 07 Q4 06 Growth (dollars in millions) Global Sales $ 1,469.7 $ 1,224.9 20.0% Constant 14.0% Currency* Full Year FY 07 FY 06 Growth (dollars in millions) Global Sales $ 5,599.6 $ 4,896.6 14.4% Constant Currency* 11.0% * Constant currency sales growth is a non-GAAP measure
Slide 5: FY 2007 Geographic Sales and Growth
FY 2007 Geographic Sales and Growth FY 2007 Sales by Geography $864.9 +21.3% Emerging Markets $2,672.5 15.5% +8.5% U.S. 47.7% Developed International 36.8% $2,062.2 +19.9% (dollars in millions) 5
Slide 6: Pharmaceutical Sales
Pharmaceutical Sales 4th Qtr Full Year $600 $2,400 +21.5% +15.3% $2,300 $550 $578.2 $2,313.8 $2,200 $500 $2,100 $2,000 $450 $475.9 $2,007.2 $1,900 $400 $1,800 Q4 2006 Q4 2007 FY 2006 FY 2007 (dollars in millions) 6
Slide 7: Glaucoma Growth Rates by Competitor
Glaucoma Growth Rates by Competitor Full Year 2007 25% +19.6% 20% Percent Growth +17.0% 15% +10.1% +10.4% 10% 5% 0% Merck Pfizer Allergan Alcon Source: Company Filings 7
Slide 8: Gaining Market Share in Pharmaceuticals
Gaining Market Share in Pharmaceuticals Global US RX Growth Sept YTD FY 2007 Brand Market Brand Market Travatan® + Travatan Z® 22.3% 9.2% 21.3% 6.5% + DuoTravTM Azopt® 14.9% 5.7% 15.7% 5.5% Vigamox® * 45.1% 8.1% 7.5% 3.5% Tobradex® 7.8% 6.7% -0.8% 1.7% Nevanac® 29.6% 2.2% 24.2% 20.6% Patanol® + Pata
Slide 9: Surgical Sales
Surgical Sales 4th Qtr Full Year $750 $2,600 +20.3% +13.4% $700 $2,500 $2,499.8 $700.8 $2,400 $650 $2,300 $600 $2,200 $550 $582.5 $2,203.8 $2,100 $500 $2,000 Q4 2006 Q4 2007 FY 2006 FY 2007 (dollars in millions) 9
Slide 10: Global Growth in Cataract Products
Global Growth in Cataract Products Percent Growth in Cataract Products – FY 2007 20% Unit Growth Dollar Growth +17.2% +16.0% 16% +13.4% +11.6% 12% +10.3% +10.0% 8% Global 4% 3.3% cataract procedure growth 0% estimate ® AcrySof IOLs Viscoelastics Phaco Disposables/ Accessories Source: Global procedur
Slide 11: US Premium IOL Sales Trend
US Premium IOL Sales Trend 2005 2006 2007 $45 $54 million $104 million $137 million +92.1% +31.4% $40.4 $40 $35 Dollars in Millions $30 $25 $20 $15 $10 $5 $- 05 05 05 05 06 06 06 06 07 07 07 07 1 2 3 4 1 2 3 4 1 2 3 4 Q Q Q Q Q Q Q Q Q Q Q Q 11
Slide 12: Consumer Eye Care Sales
Consumer Eye Care Sales 4th Qtr Full Year $225 $850 +14.5% +14.6% $800 $200 $750 $786.0 $175 $190.7 $700 $150 $166.5 $650 $685.6 $125 $600 Q4 2006 Q4 2007 FY 2006 FY 2007 (dollars in millions) 12
Slide 13: US Market Share Since April 2007
US Market Share Since April 2007 Avg share for 12 weeks ending 45% 12/29/07 12/28/06 40% Alcon* 39.3% 34.0% 35% 12 Week Average 30% Market Share Market Share 25% Private 21.5% 24.6% 20% Label B&L 17.6% 16.8% 15% Ciba 15.3% 12.2% 10% 5% AMO 4.6% 9.1% 0% *OPTI-FREE® EXPRESS® and RepleniSH® combined 7
Slide 14: Financial Review
Financial Review Rick Croarkin Senior Vice President, Finance and Chief Financial Officer 14
Slide 15: Non-GAAP Adjustments
Non-GAAP Adjustments Q4 Full Year Op Profit After Tax Op Profit After Tax 2007 WaveLight Acquisition & $ 21.1 $ 16.8 $ 26.4 $ 20.2 Refractive Integration Refractive Impairment -- -- 32.7 20.8 2006 Patent Lawsuit $ -- $ -- $ (119.0) $ (97.5) Settlement Refractive Impairment -- -- 144.8 92.0 (dollars
Slide 16: Gross Profit
Gross Profit % of % of 4th Qtr Q4 07 Sales Q4 06 Sales (dollars in millions) Gross Profit Reported $ 1,098.4 74.7% $ 924.7 75.5% Non-GAAP (1.9) -- Adjustment* Adjusted $ 1,096.5 75.4% $ 924.7 75.5% % of % of Full Year FY 07 Sales FY 06 Sales (dollars in millions) Gross Profit Reported $ 4,201.4 75.0
Slide 17: Operating Profit
Operating Profit % of % of 4th Qtr Q4 07 Sales Q4 06 Sales (dollars in millions) Operating Profit Reported $ 477.4 32.5% $ 392.9 32.1% Non-GAAP 21.1 -- Adjustment* Adjusted $ 498.5 34.3% $ 392.9 32.1% % of % of Full Year FY 07 Sales FY 06 Sales (dollars in millions) Operating Profit Reported $ 1,883
Slide 18: Net Earnings
Net Earnings % of % of 4th Qtr Q4 07 Sales Q4 06 Sales (dollars in millions) Net Earnings Reported $ 376.5 25.6% $ 354.7 29.0% Non-GAAP 16.8 -- Adjustment* Adjusted $ 393.3 27.0% $ 354.7 29.0% % of % of Full Year FY 07 Sales FY 06 Sales (dollars in millions) Net Earnings Reported $ 1,586.4 28.3% $ 1
Slide 19: Diluted EPS
Diluted EPS 4th Qtr Q4 07 Q4 06 Growth Diluted EPS Reported $ 1.25 $ 1.16 7.8% Non-GAAP 0.06 -- Adjustment* Adjusted $ 1.31 $ 1.16 12.9% Full Year Q4 07 Q4 06 Growth Diluted EPS Reported $ 5.25 $ 4.37 20.1% Non-GAAP 0.14 (0.02) Adjustment* Adjusted $ 5.39 $ 4.35 23.9% * Non-GAAP measures – Adjustmen
Slide 20: Cash Flow Analysis
Cash Flow Analysis Cash Flow from Operations $1,600 $1,469.5 $1,405.9 $1,400 Dollars in millions $1,235.0 $1,200 $1,047.8 $1,000 $915.4 $800 $600 2003 2004 2005 2006 2007 % Reinvested 17.2% 14.0% 13.1% 15.8% 15.5% into PPE 20
Slide 21: Net Cash Returned to Shareholders
Net Cash Returned to Shareholders $1,800 Share Repurchases $1,616 $1,600 Dividends $1,400 $1,316 dollars in millions $1,200 $1,003 $1,000 $899 $800 $694 $600 $406 $392 $400 $236 $613 $200 $141 $417 $34 $302 $170 $107 $0 2003 2004 2005 2006 2007 Dividend 23.0% 28.5% 34.6% 44.8% 45.5% Payout Ratio* *
Slide 22: 2008 Full Year Financial Guidance
2008 Full Year Financial Guidance • Sales range of $6,175 to $6,275 million • Diluted earnings per share range of $6.24 to $6.30 • Includes costs to establish Swiss Shared Service and Marketing Centers and to integrate refractive operations 22
Slide 23: Alcon
Alcon
Slide 24: Q4 2007 Non-GAAP Adjustments
Q4 2007 Non-GAAP Adjustments (dollars in millions, except per share amounts) WaveLight Acquisition & Refractive Non-GAAP Reported Integration Adjusted* Sales $ 1,469.7 $ (15.1) $ 1,454.6 Cost of goods sold 371.3 (13.2) 358.1 Gross profit 1,098.4 (1.9) 1,096.5 Selling, general and administrative 441.
Slide 25: FY 2007 Non-GAAP Adjustments
FY 2007 Non-GAAP Adjustments WaveLight (dollars in millions, except per share amounts) Acquisition & Refractive Refractive Non-GAAP Reported Impairment Integration Adjusted* Sales $ 5,599.6 $ -- $ (15.1) $ 5,584.5 Cost of goods sold 1,398.2 (24.0) (16.4) 1,357.8 Gross profit 4,201.4 24.0 1.3 4,226.7
Slide 26: FY 2006 Non-GAAP Adjustments
FY 2006 Non-GAAP Adjustments Non-GAAP Adjustment (dollars in millions, except per share amounts) Patent Lawsuits Refractive Non-GAAP Reported Settlement Impairment Adjusted* Sales $ 4,896.6 $ -- $ -- $ 4,896.6 Cost of goods sold 1,215.1 -- (19.1) 1,196.0 Gross profit 3,681.5 -- 19.1 3,700.6 Selling,